Relay Therapeutics (RLAY) EBITDA Margin (2021 - 2026)
Relay Therapeutics (RLAY) reported EBITDA Margin of 2448.77% for Q1 2026, down 145859.0% year-over-year from N/an in Q1 2025, and down 213.66% quarter-over-quarter from 780.71% in Q4 2025.
Relay Therapeutics (RLAY) EBITDA Margin (2021 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has 6 years of EBITDA Margin data on file, last reported at 2448.77% in Q1 2026.
- EBITDA Margin for Q1 2026 came in at 2448.77%, down 145859.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 2549.24% (up 177672.0% YoY), and the FY2025 annual result was 1789.35%, up 159331.0% from the prior year.
- EBITDA Margin eased to 2448.77% in Q1 2026 per RLAY's latest filing, from 780.71% in the prior quarter.
- Over five years, EBITDA Margin peaked at 8030500.0% in Q4 2023 and troughed at 83011.76% in Q2 2023.
- A 5-year average of 600245.04% and a median of 10424.82% in 2025 frame the typical range for EBITDA Margin.
- On a YoY basis, EBITDA Margin climbed as much as 805600751 bps in 2023 and fell as far as 6123752 bps in 2023.
- A 5-year view of EBITDA Margin shows it stood at 25507.51% in 2022, then jumped by 31583 bps to 8030500.0% in 2023, then plunged by 100 bps to 822.91% in 2024, then climbed by 5 bps to 780.71% in 2025, then slumped by 214 bps to 2448.77% in 2026.
- Business Quant data shows RLAY's EBITDA Margin at 2448.77% in Q1 2026, 780.71% in Q4 2025, and 10424.82% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Relay Therapeutics | 2.86 Bn | 2.86 Bn | - | -2,448.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,448.77% |
| Dec 31, 2025 | -780.71% |
| Jun 30, 2025 | -10,424.82% |
| Mar 31, 2025 | -990.18% |
| Mar 31, 2024 | -822.91% |
| Dec 31, 2023 | 8,030,500.00% |
| Sep 30, 2023 | -250.13% |
| Jun 30, 2023 | -83,011.76% |
| Mar 31, 2023 | -39,655.31% |
| Dec 31, 2022 | -25,507.51% |
| Sep 30, 2022 | -24,899.71% |
| Jun 30, 2022 | -21,774.25% |
| Mar 31, 2022 | -16,748.45% |
| Dec 31, 2021 | -12,090.65% |
| Sep 30, 2021 | -9,122.97% |
| Jun 30, 2021 | -22,923.58% |
| Mar 31, 2021 | -4,436.55% |